Laboratory evaluation of the Anyplex? II MTB/MDR and MTB/XDR tests based on multiplex real-time PCR and melting-temperature analysis to identify Mycobacterium tuberculosis and drug resistance

摘要

Abstract We evaluated the performance of two multiplex, real-time PCR tests (Anyplex II MTB/MDR and MTB/XDR; Seegene, Seoul, Korea), designed to detect the Mycobacterium tuberculosis complex (MTC) and drug-resistance mutations associated with isoniazid, rifampicin, fluoroquinolones, and second-line injectable drugs. We analyzed 122 clinical isolates with the Anyplex II MTB/MDR test, 68 of which were also tested with the Anyplex II MTB/XDR test. The Anyplex II MTB/MDR and MTB/XDR tests showed the following respective sensitivities and specificities: 68.8% and 100% for detecting isoniazid resistance, 93.8% and 100% for rifampicin, 82.8% and 100% for levofloxacin, 75.0% and 100% for kanamycin, and 92.6% and 100% for MTC identification. These kits correctly identified 61.8% of multi-drug resistant M. tuberculosis isolates and 64.7% of extensively drug-resistant M. tuberculosis isolates, and enabled semi-automatic detection of drug-resistant MTC in 3 hours. The Anyplex II kits could be useful as rule-in tests for detecting MTC and drug resistance. Highlight ? The Anyplex II MTB/MDR and MTB/XDR tests (Seegene, Korea) are semi-automated real-time PCR and analysis systems for identifying multidrug-resistant M. tuberculosis and extensively drug-resistant M. tuberculosis. ? High diagnostic performance for MTB identification and drug resistance detection were shown for the Anyplex II MTB/MDR and MTB/XDR. ? The Anyplex II MTB/MDR and MTB/XDR tests could be useful as rule-in tests for detecting MDR and XDR-TB.